BL
Highly rated in
10
conditions
Highly rated in
10
conditions
Check Dr. Benjamin P. Levy's experience treating your condition:
About Dr. Benjamin P. Levy

Benjamin Levy is an Oncologist and a Hematologist Oncology expert in Washington, Washington, D.c.. Levy has been practicing medicine for over 21 years and is highly rated in 10 conditions, according to our data. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NCSLC), Squamous Cell Lung Carcinoma, EGFR Positive Lung Cancer, and Tissue Biopsy. He is licensed to treat patients in Maryland and New York. Levy is currently accepting new patients.

His clinical research consists of co-authoring 61 peer reviewed articles and participating in 6 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Benjamin P. Levy it is best to call his office and ask if your insurance is accepted.

Accepts Medicare

Dr. Benjamin P. Levy accepts the following insurance:

  •  Ambetter
  •  CareFirst

Call to see if your plan is accepted.
Locations
5255 Loughboro Rd Nw, Washington, DC 20016
Background & Education
Graduate Institution
Other, 2002
Specialties
Oncology
Hematology Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Sibley Memorial Hospital
Languages Spoken
English
Gender
Male
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


6 Clinical Trials

Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)
View 2 Less Clinical Trial -

61 Total Publications

Relapsed small-cell lung cancer: a disease of continued unmet need.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors